 STAT3 Transcription Factor
"STAT3 Transcription Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130.
| Descriptor ID |
D050796
|
| MeSH Number(s) |
D12.644.360.024.342.300 D12.776.157.057.186.300 D12.776.476.024.421.300 D12.776.930.840.300
|
| Concept/Terms |
STAT3 Transcription Factor- STAT3 Transcription Factor
- Transcription Factor, STAT3
- APRF Transcription Factor
- Transcription Factor, APRF
- IL6-Response Factor
- IL6 Response Factor
- Signal Transducer and Activator of Transcription 3
- STAT3 Protein
- Acute-Phase Response Factor
- Acute Phase Response Factor
- Response Factor, Acute-Phase
- LIF-Response Factor
- LIF Response Factor
STAT3a Transcription Factor- STAT3a Transcription Factor
- Transcription Factor, STAT3a
- Stat3alpha Transcription Factor
- Transcription Factor, Stat3alpha
STAT3b Transcription Factor- STAT3b Transcription Factor
- Transcription Factor, STAT3b
- Stat3beta Transcription Factor
- Transcription Factor, Stat3beta
|
Below are MeSH descriptors whose meaning is more general than "STAT3 Transcription Factor".
Below are MeSH descriptors whose meaning is more specific than "STAT3 Transcription Factor".
This graph shows the total number of publications written about "STAT3 Transcription Factor" by people in this website by year, and whether "STAT3 Transcription Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 2 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 2 | 4 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 1 | 2 | | 2015 | 4 | 1 | 5 | | 2016 | 2 | 0 | 2 | | 2017 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "STAT3 Transcription Factor" by people in Profiles.
-
Brown CW, Amante JJ, Goel HL, Mercurio AM. The a6ß4 integrin promotes resistance to ferroptosis. J Cell Biol. 2017 12 04; 216(12):4287-4297.
-
Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
-
Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H. ?Np63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget. 2016 Jul 26; 7(30):48533-48546.
-
Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652.
-
Kim ES, Agarwal S, Shohet JM. G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response. Cancer Res. 2015 Sep 15; 75(18):3992.
-
Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, Ferris R, Kao J, Wang LH, Pan PY, Ko EC, Chen SH. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res. 2015 Sep 15; 21(18):4073-4085.
-
Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM. G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res. 2015 Jun 15; 75(12):2566-79.
-
Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015 Apr 13; 27(4):516-32.
-
Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jun; 24(6):809-24.
-
Mizushina Y, Shirasuna K, Usui F, Karasawa T, Kawashima A, Kimura H, Kobayashi M, Komada T, Inoue Y, Mato N, Yamasawa H, Latz E, Iwakura Y, Kasahara T, Bando M, Sugiyama Y, Takahashi M. NLRP3 protein deficiency exacerbates hyperoxia-induced lethality through Stat3 protein signaling independent of interleukin-1ß. J Biol Chem. 2015 Feb 20; 290(8):5065-77.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|